bs_bs_banner
46
Sydney Cancer Conference 2014
Sponsors and Exhibitors The following companies and organisations are proud supporters of the Sydney Cancer Conference 2014: Bayer is an international, research-based company specialising in healthcare, nutrition and high-tech materials. It has operated in Australia since 1925 and has a long term commitment to the health of all Australians. The company’s focus on people, partnerships and innovation underpins all aspects of its operations, consistent with its mission, “Bayer: Science For A Better Life.” http://www.bayer.com.au
The Cancer Institute NSW is Australia’s first statewide cancer control agency, established under the Cancer Institute NSW (2003) Act to lessen the impact of cancer in NSW. The Institute supports and promotes best practice; working to ensure people across the state, no matter where they live, are provided the same high quality treatment and care that is vital to optimising the outcomes and quality of life for people diagnosed with cancer. Driven by the purpose and objectives of the NSW Cancer Plan 2011–15, the Institute continuously works to: • reduce the incidence of cancer • increase the survival rate for people with cancer • improve the quality of life of people living with cancer • provide a source of expertise on cancer control for the government, health service providers, medical researchers and the general community. In order to achieve this, the Institute engages with the community, health professionals, researchers, governments and charity organisations to: • provide information, resources and advice about preventing cancer • promote the importance of early detection through cancer screening programs • provide grants that build research capacity and foster innovation in, and translation of, cancer research • maintain quality information repositories about cancer in NSW to inform future policy and health planning • establish partnerships with cancer healthcare professionals to develop and evaluate programs to improve the quality of cancer treatment and care in NSW. www.cancerinstitute.org.au
Sponsors and Exhibitors
47
Life Technologies™ products harness the power of science to transform lives. As a member of the Thermo Fisher Scientific family of brands, our instruments, everyday tools, and services offer high-quality, innovative life science solutions for every lab and application. Go to lifetechnologies.com to learn more.
Lilly Oncology has an unwavering focus on helping, and improving outcomes for individual patients with cancer and the clinicians who treat them. For more than five decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the lives of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches and speeding innovation. Currently with one of the most robust oncology pipelines, our quest is to build on our strong heritage by further developing a broad portfolio of tailored therapies that accelerate the pace and progress of cancer care.
Today’s MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd-australia.com.au.
The NHMRC Clinical Trials Centre (NHMRC CTC) is a major Australian academic research organisation, recognised worldwide as a centre of excellence in clinical trials research. We specialise in: • clinical trials design, development, conduct and reporting in cardiovascular disease, diabetes, neonatology and oncology • biostatistics • systematic reviews • health economics • translational research (bench to bedside, evidence into practice) Our mission is to achieve best practice in health care and improve outcomes in Australia and internationally through the better use of clinical trials research. With over 20 years’ experience, the NHMRC CTC generates 60+ publications annually and has strong links with the national Cancer Co-operative Trial Groups, granting bodies and industry. Visit us at www.ctc.usyd.edu.au orcontact us at [email protected]
48
Sydney Cancer Conference 2014
NSW Trade & Investment is the lead economic development agency in New South Wales, Australia responsible for driving sustainable economic growth across the state. We achieve results by collaborating with and supporting businesses, industries and communities to advance investment, trade, innovation, productivity and regional growth across all sectors. We work with local, national and international customers to deliver our services. Our purpose is to develop a competitive and sustainable NSW economy. Our vision is a strong NSW economy built on resilient communities. WHO WE ARE: Sydney Catalyst is a Sydney-based translational cancer research centre that includes outstanding teams of researchers and clinicians from our 20+ member institutions and groups across NSW. WHAT WE DO: We aim to improve health outcomes for people affected by cancer through a translational research program supporting basic scientific discovery and translation of evidence into practice. HOW WE DO IT: We connect. Sydney Catalyst facilitates communication and collaboration between the multiple disciplines and institutions that make up our membership. We’re here to introduce, unite and collaborate. We love nothing more than helping our members join forces to achieve common goals across the full spectrum of translational cancer research. WHO WE CONNECT: We aim to successfully and productively bring together disciplines, groups and individuals who do not traditionally work together, and to do so in a way that encourages meaningful collaboration; work that would not have happened otherwise. For more information, visit www.sydneycatalyst.org.au
The Ian Potter Foundation is one of Australia’s major philanthropic foundations. The Foundation makes grants nationally to support charitable organisations working to benefit the community across a wide range of sectors including the Arts, environment, science, medical research, education and community wellbeing. The Ian Potter Foundation aims to support and promote a healthy, vibrant and fair community for the benefit of all Australians.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Copyright of Asia Pacific Journal of Clinical Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.
46
Sydney Cancer Conference 2014
Sponsors and Exhibitors The following companies and organisations are proud supporters of the Sydney Cancer Conference 2014: Bayer is an international, research-based company specialising in healthcare, nutrition and high-tech materials. It has operated in Australia since 1925 and has a long term commitment to the health of all Australians. The company’s focus on people, partnerships and innovation underpins all aspects of its operations, consistent with its mission, “Bayer: Science For A Better Life.” http://www.bayer.com.au
The Cancer Institute NSW is Australia’s first statewide cancer control agency, established under the Cancer Institute NSW (2003) Act to lessen the impact of cancer in NSW. The Institute supports and promotes best practice; working to ensure people across the state, no matter where they live, are provided the same high quality treatment and care that is vital to optimising the outcomes and quality of life for people diagnosed with cancer. Driven by the purpose and objectives of the NSW Cancer Plan 2011–15, the Institute continuously works to: • reduce the incidence of cancer • increase the survival rate for people with cancer • improve the quality of life of people living with cancer • provide a source of expertise on cancer control for the government, health service providers, medical researchers and the general community. In order to achieve this, the Institute engages with the community, health professionals, researchers, governments and charity organisations to: • provide information, resources and advice about preventing cancer • promote the importance of early detection through cancer screening programs • provide grants that build research capacity and foster innovation in, and translation of, cancer research • maintain quality information repositories about cancer in NSW to inform future policy and health planning • establish partnerships with cancer healthcare professionals to develop and evaluate programs to improve the quality of cancer treatment and care in NSW. www.cancerinstitute.org.au
Sponsors and Exhibitors
47
Life Technologies™ products harness the power of science to transform lives. As a member of the Thermo Fisher Scientific family of brands, our instruments, everyday tools, and services offer high-quality, innovative life science solutions for every lab and application. Go to lifetechnologies.com to learn more.
Lilly Oncology has an unwavering focus on helping, and improving outcomes for individual patients with cancer and the clinicians who treat them. For more than five decades, Lilly Oncology has been dedicated to delivering innovative solutions that improve the lives of people living with cancer. Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches and speeding innovation. Currently with one of the most robust oncology pipelines, our quest is to build on our strong heritage by further developing a broad portfolio of tailored therapies that accelerate the pace and progress of cancer care.
Today’s MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd-australia.com.au.
The NHMRC Clinical Trials Centre (NHMRC CTC) is a major Australian academic research organisation, recognised worldwide as a centre of excellence in clinical trials research. We specialise in: • clinical trials design, development, conduct and reporting in cardiovascular disease, diabetes, neonatology and oncology • biostatistics • systematic reviews • health economics • translational research (bench to bedside, evidence into practice) Our mission is to achieve best practice in health care and improve outcomes in Australia and internationally through the better use of clinical trials research. With over 20 years’ experience, the NHMRC CTC generates 60+ publications annually and has strong links with the national Cancer Co-operative Trial Groups, granting bodies and industry. Visit us at www.ctc.usyd.edu.au orcontact us at [email protected]
48
Sydney Cancer Conference 2014
NSW Trade & Investment is the lead economic development agency in New South Wales, Australia responsible for driving sustainable economic growth across the state. We achieve results by collaborating with and supporting businesses, industries and communities to advance investment, trade, innovation, productivity and regional growth across all sectors. We work with local, national and international customers to deliver our services. Our purpose is to develop a competitive and sustainable NSW economy. Our vision is a strong NSW economy built on resilient communities. WHO WE ARE: Sydney Catalyst is a Sydney-based translational cancer research centre that includes outstanding teams of researchers and clinicians from our 20+ member institutions and groups across NSW. WHAT WE DO: We aim to improve health outcomes for people affected by cancer through a translational research program supporting basic scientific discovery and translation of evidence into practice. HOW WE DO IT: We connect. Sydney Catalyst facilitates communication and collaboration between the multiple disciplines and institutions that make up our membership. We’re here to introduce, unite and collaborate. We love nothing more than helping our members join forces to achieve common goals across the full spectrum of translational cancer research. WHO WE CONNECT: We aim to successfully and productively bring together disciplines, groups and individuals who do not traditionally work together, and to do so in a way that encourages meaningful collaboration; work that would not have happened otherwise. For more information, visit www.sydneycatalyst.org.au
The Ian Potter Foundation is one of Australia’s major philanthropic foundations. The Foundation makes grants nationally to support charitable organisations working to benefit the community across a wide range of sectors including the Arts, environment, science, medical research, education and community wellbeing. The Ian Potter Foundation aims to support and promote a healthy, vibrant and fair community for the benefit of all Australians.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Copyright of Asia Pacific Journal of Clinical Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.
